ValuEngine Upgrades Cyclacel Pharmaceuticals (NASDAQ:CYCC) to Hold

Share on StockTwits

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, ValuEngine reports.

Separately, Zacks Investment Research raised Cyclacel Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.50 price target for the company in a report on Monday, November 18th.

Shares of NASDAQ CYCC opened at $0.52 on Tuesday. The business has a fifty day moving average of $0.42 and a two-hundred day moving average of $0.49. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.65 and a current ratio of 7.65. Cyclacel Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $1.18. The stock has a market cap of $9.46 million, a PE ratio of -0.85 and a beta of 3.19.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC lifted its holdings in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,102,400 shares of the biotechnology company’s stock after buying an additional 498,200 shares during the quarter. Renaissance Technologies LLC owned about 6.41% of Cyclacel Pharmaceuticals worth $596,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 9.20% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Further Reading: Key terms to understand channel trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.